Dupont Capital Management Corp Amicus Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	SELL	$9.82 - $12.75 $280,370 - $364,025	-28,551 Reduced 76.33%	8,856 $92,000
Q1 2022 Apr 27, 2022	SELL	$7.89 - $12.48 $26,108 - $41,296	-3,309 Reduced 8.13%	37,407 $354,000
Q4 2021 Jan 31, 2022	SELL	$9.82 - $12.44 $159,417 - $201,950	-16,234 Reduced 28.51%	40,716 $470,000
Q3 2021 Nov 03, 2021	SELL	$8.74 - $11.84 $70,357 - $95,312	-8,050 Reduced 12.38%	56,950 $544,000
Q1 2021 Apr 29, 2021	BUY	$9.2 - $23.86 $340,142 - $882,151	36,972 Added 131.91%	65,000 $642,000
Q4 2020 Jan 28, 2021	SELL	$13.47 - $24.89 $28,179 - $52,069	-2,092 Reduced 6.95%	28,028 $647,000
Q3 2020 Oct 29, 2020	SELL	$12.89 - $15.89 $26,012 - $32,066	-2,018 Reduced 6.28%	30,120 $425,000
Q2 2020 Jul 24, 2020	SELL	$8.86 - $15.69 $25,428 - $45,030	-2,870 Reduced 8.2%	32,138 $485,000
Q3 2019 Oct 28, 2019	BUY	$8.02 - $13.25 $280,764 - $463,856	35,008 New	35,008 $281,000

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.